Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a costimulatory molecule that negatively regulates T-cell activation. Originally identified in murine CD8+ T cells, it has been found to be rapidly induced on human T cells. Furthermore, CTLA-4 is expressed on regulatory T cells. Clinically, targeting CTLA-4 has clinical utility in the treatment of melanoma. Whether the expression of CTLA-4 is differentially regulated in CD8+ vs CD4+ human T cells is unclear. Here, we analyzed CTLA-4 in normal human CD4+ and CD8+ T-cell subsets and show for the first time that CTLA-4 is expressed significantly higher in the CD4+ T cells than in CD8+ T cells. CTLA-4 is higher at the protein and the transcriptional levels in CD4+ T cells. This increase is due to the activation of the CTLA-4 promoter, which undergoes acetylation at the proximal promoter. Furthermore, we show that blocking CTLA-4 on CD4+ T cells permits greater proliferation in CD4+ vs CD8+ cells. These findings demonstrate a differential regulation of CTLA-4 on CD4+ and CD8+ T-cell subsets, which is likely important to the clinical efficacy for anti-CTLA-4 therapies. The findings hint to strategies to modulate CTLA-4 expression by targeting epigenetic transcription to alter the immune response.

• Publication year

  2013

• Venue

  Genes and Immunity

• Publication date

  2013-10-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/gene.2013.57PMID 24173147PMCID 4284071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

  2012cited by this paper
• CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

  2012cited by this paper
• CTLA-4: Not All Costimulation Is Stimulatory

  2011cited by this paper
• Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465.

  2011cited by this paper
• CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

  2011cited by this paper
• Generation and function of immunosuppressive human and murine CD8+ T cells by transforming growth factor‐β and retinoic acid

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

  2010cited by this paper
• Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity

  2010cited by this paper
• Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

  2010cited by this paper
• CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity1

  2009cited by this paper
• CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

  2009cited by this paper
• Impaired NFAT Transcriptional Activity in Antigen-Stimulated CD8 T Cells Linked to Defective Phosphorylation of NFAT Transactivation Domain1

  2009cited by this paper
• FOXP3 Inhibits Activation-Induced NFAT2 Expression in T Cells Thereby Limiting Effector Cytokine Expression1

  2009cited by this paper
• Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

  2008cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• High IFN-γ Production of Individual CD8 T Lymphocytes Is Controlled by CD152 (CTLA-4)1

  2007cited by this paper
• Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter1

  2007cited by this paper
• High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4).

  2007cited by this paper
• Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

  2006cited by this paper
• Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells

  2006cited by this paper
• CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

  2006cited by this paper
• FOXP3 controls regulatory T cell function through cooperation with NFAT.

  2006cited by this paper
• TGF-β Requires CTLA-4 Early after T Cell Activation to Induce FoxP3 and Generate Adaptive CD4+CD25+ Regulatory Cells1

  2006cited by this paper
• Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma.

  2006cited by this paper
• Differential expression of CTLA‐4 among T cell subsets

  2004cited by this paper
• Expression of CTLA‐4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection

  2004cited by this paper
• Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

  2003cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Polymorphism of the CTLA-4 Gene Is Associated with Autoimmune Hypothyroidism in the United Kingdom

  2002cited by this paper
• Regulation of the Murine Nfatc1 Gene by NFATc2*

  2002cited by this paper
• Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28.

  2002cited by this paper
• CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production.

  2001cited by this paper
• Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B.

  2001cited by this paper
• The United Kingdom

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

  2001cited by this paper
• Use of Chromatin Immunoprecipitation To Clone Novel E2F Target Promoters

  2001cited by this paper
• Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4

  2000cited by this paper
• The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

  2000cited by this paper
• T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells.

  1999cited by this paper
• Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.

  1999cited by this paper
• Expression and function of CTLA-4 in Th1 and Th2 cells.

  1998cited by this paper
• Expression and Function of CTLA-4 in Th 1 and Th 2 Cells

  1998cited by this paper
• CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

  1997cited by this paper
• Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups.

  1997cited by this paper
• A CTLA‐4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism

  1997cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• Regulation of CTLA-4 expression during T cell activation.

  1996cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

  1995cited by this paper
• Distinct pattern of IL-2 and IFN-gamma gene expression in CD4 and CD8 T cells: cytofluorometric analysis at a single cell level using non-radioactive probes.

  1995cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• CTLA-4 can function as a negative regulator of T cell activation.

  1994cited by this paper
• Characterization of CTLA-4 structure and expression on human T cells.

  1993cited by this paper
• CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.

  1992cited by this paper
• CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.

  1991cited by this paper
• Human Ig superfamily CTLA‐4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA‐4 cytoplasmic domains

  1988cited by this paper
• Modulation of CD4 by antigenic activation.

  1987cited by this paper
• A new member of the immunoglobulin superfamily—CTLA-4

  1987cited by this paper

• Aqueous Humor Exosomal Membrane Proteins: Decoding Pathogenic Molecular Signatures in Retinitis Pigmentosa

  2025cites this paper
• Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update

  2025cites this paper
• CD4+ T cell dysfunction in cancer.

  2025cites this paper
• Novel pathogenic variants in CTLA4 and LRBA immune dysregulation: Reduced CTLA-4 expression with normal expression of co-stimulatory surface molecules.

  2025cites this paper
• Cytometric Analysis of CD3 + CD4 + T Populations and Activation and Regulation Status of Naïve and Memory CD4 + CD45RA T Cells in Immunocompetent Patients with Neurocryptococcosis

  2025cites this paper
• Causal associations between neuroinflammation-related genes and intracerebral hemorrhage: an integrated study of Mendelian Randomization and gene functional analysis

  2025cites this paper
• Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy

  2025cites this paper
• Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines.

  2025cites this paper
• Paradoxical Effect of Myosteatosis on the Immune Checkpoint Inhibitor Response in Metastatic Renal Cell Carcinoma

  2025cites this paper
• Immunophenotypical characterization of immune checkpoint receptor expression in cynomolgus monkeys and human healthy volunteers in resting and in T-cell stimulatory conditions in vitro

  2025cites this paper
• Astragalus root increases Treg and Th17 involvement in embryo implantation and pregnancy maintenance by decreasing CTLA-4+ Tregs.

  2024cites this paper
• Anti-leishmanial therapies: overcoming current challenges with emerging therapies

  2024cites this paper
• Combination of radiotherapy and immunotherapy in duality with the protumoral action of radiation.

  2024cites this paper
• Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy

  2024cites this paper
• Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients

  2024cites this paper
• Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

  2024cites this paper
• The Effect of Interval Training and Urtica Dioica Hydroalcoholic Extract on some Growth and Immune Factors in C57 Rats with Melanoma Cancer

  2024cites this paper
• Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice

  2024cites this paper
• Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells

  2024cites this paper
• Novel technologies for applying immune checkpoint blockers.

  2024cites this paper
• Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

  2023cites this paper
• Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.

  2023cites this paper
• The Cytomorphology of Melanoma with a Special Emphasis on the Immune Checkpoint Proteins CTLA-4, PD-1, and PD-L1

  2023cites this paper
• Fine-mapping causal tissues and genes at disease-associated loci

  2023cites this paper
• Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma

  2023cites this paper
• Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies

  2023cites this paper
• Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

  2023cites this paper
• Turning up the heat: CTLA4 blockade in urothelial cancer

  2023cites this paper
• Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

  2023cites this paper
• Smart probes for optical imaging of T cells and screening of anti-cancer immunotherapies

  2023cites this paper
• The Expression of CTLA-4 in Breast Tumors and Tumor-Infiltrating Leukocytes Affects Patients’ Systemic Inflammatory Status and Varies According to Their Molecular Subtypes

  2023cites this paper
• T-cell receptor signaling modulated by the co-receptors: Potential targets for stroke treatment.

  2023cites this paper
• Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB

  2023cites this paper
• Immunomodulatory Effects of New Phenanthrene Derivatives from Dendrobium crumenatum.

  2023cites this paper
• Identification of ulcerative colitis-specific immune cell signatures from public single-cell RNA-seq data

  2023cites this paper
• The interactions of docetaxel with tumor microenvironment.

  2023cites this paper
• Recent Advances and Research Progress in Biomarkers for Chronic Graft Versus Host Disease.

  2023cites this paper
• Development of a Highly Sensitive Hybrid LC/MS Assay for the Quantitative Measurement of CTLA-4 in Human T Cells

  2023cites this paper
• Stress-induced immunosuppression affecting immune response to Newcastle disease virus vaccine through “miR-155-CTLA-4” pathway in chickens

  2023cites this paper
• Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model

  2023influential citation
• Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion

  2023cites this paper
• Circadian rhythm-related factors of PER and CRY family genes function as novel therapeutic targets and prognostic biomarkers in lung adenocarcinoma

  2022cites this paper
• Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence

  2022cites this paper
• Integrative Multi−Omics Analysis Reveals Candidate Biomarkers for Oral Squamous Cell Carcinoma

  2022cites this paper
• Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

  2022cites this paper
• Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T-cell Responses Against Medulloblastoma

  2022cites this paper
• Association of CTLA-4 (+49A/G) polymorphism and susceptibility of developing rheumatoid arthritis in an Iraqi Arab population

  2022cites this paper
• Biology and Natural History of Type 1 Diabetes Mellitus.

  2022cites this paper
• Increased percentage of apoptotic and CTLA-4 (CD152) expressing cells in CD4+/CD8+ cells in COVID-19 patients

  2022cites this paper
• Systemic benefit of radiation therapy via abscopal effect

  2022cites this paper
• Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives

  2022cites this paper
• Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions

  2022cites this paper
• Cancer Exosomes: An Overview and the Applications of Flow

  2022cites this paper
• Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines

  2021cites this paper
• Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle

  2021cites this paper
• Antigenic Challenge Influences Epigenetic Changes in Antigen-Specific T Regulatory Cells

  2021cites this paper
• Translational and clinical aspects of pancreatic cancer

  2021cites this paper
• CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade

  2021cites this paper
• The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review

  2021cites this paper
• B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion

  2021cites this paper
• Long-term neuropathic pain behaviors correlate with synaptic plasticity and limbic circuit alteration: a comparative observational study in mice

  2021cites this paper
• Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

  2021cites this paper
• Immunotherapy Resistance in Glioblastoma

  2021cites this paper
• The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities

  2021cites this paper
• Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer

  2021cites this paper
• Co-inhibitory receptors, transcription factors and tolerance.

  2020cites this paper
• Costimulation Blockade Disrupts CD4+ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes

  2020cites this paper
• Strategies to Target Tumor Immunosuppression

  2020cites this paper
• Current Advances in the Treatment of BRAF-Mutant Melanoma

  2020cites this paper
• Peptide-based targeting of immunosuppressive cells in cancer

  2020cites this paper
• Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

  2020cites this paper
• The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part II: B7-1, B7-2, B7-H2, B7-H3, B7-H4, B7-H5 (VISTA), B7-H6 and B7-H7

  2020cites this paper
• Immune checkpoint proteins CTLA-4, PD-1 and PD-L1 in melanoma as predictive biomarkers to guide clinical decisions

  2020cites this paper
• Molecular Pathology of Immune Checkpoint Inhibitor-Induced Myocarditis

  2020cites this paper
• An interpretable deep-learning architecture of capsule networks for identifying cell-type gene expression programs from single-cell RNA-sequencing data

  2020cites this paper
• Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

  2020cites this paper
• European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

  2020cites this paper
• Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy

  2020cites this paper
• Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?

  2020cites this paper
• Anti-CTLA-4 Antibody-Functionalized Dendritic Cell-derived Exosomes Targeting Tumor-draining Lymph Nodes for Effective Induction of Antitumor T-cell Responses.

  2020cites this paper
• CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses

  2020cites this paper
• CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro

  2019cites this paper
• Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment

  2019cites this paper
• CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers

  2019cites this paper
• CTLA-4 (CD152): A versatile receptor for immune-based therapy.

  2019cites this paper
• MicroRNAs and immunomodulation by vitamin D

  2019cites this paper
• Clinical development of targeted and immune based anti-cancer therapies

  2019cites this paper
• Augmenting the synergies of chemotherapy and immunotherapy through drug delivery.

  2019cites this paper
• Immune therapy of melanoma: Overview of therapeutic vaccines

  2019cites this paper
• Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

  2019cites this paper
• CTLA-4 +49 G/A, a functional T1D risk SNP, affects CTLA-4 level in Treg subsets and IA-2A positivity, but not beta-cell function

  2018cites this paper
• MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function

  2018cites this paper
• Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4

  2018cites this paper
• Evolution of Cancer, Adaptive Immunity, and Immunotherapy

  2018cites this paper
• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

  2018cites this paper
• Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.

  2017cites this paper
• This information is current as Migration and CTLA-4 Center Responses by Controlling Cell Helper Cell Differentiation and Germinal Foxp 1 Negatively Regulates T Follicular

  2017cites this paper
• Altered expression of CTLA-4, CD28, VDR, and CD45 mRNA in T cells of patients with Hashimoto’s thyroiditis — a pilot study

  2017cites this paper
• T cell resistance to activation by dendritic cells requires long-term culture in simulated microgravity.

  2017cites this paper
• Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer

  2017cites this paper